Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: The pitavastatin heart failure study (PEARL study)
International Journal of Cardiology, 03/30/2012Mizuma H et al.
The PEARL study will provide important data on the role of pitavastatin in the treatment of Japanese patients with mildly symptomatic heart failure.
577 patients with chronic heart failure were enrolled.
Authors used a prospective, randomized, open–label, and blinded–endpoint evaluation (PROBE) design.
Patients aged 20–79years old with symptomatic (NYHA functional class II or III) heart failure and a left ventricular ejection fraction of ≤45% were randomly allocated to either receive pitavastatin (2mg/day) or not in addition to conventional therapy for heart failure by using the minimization method.
Follow–up will be continued until March 2011.
The primary endpoint is a composite of cardiac death and hospitalization for worsening heart failure.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.